Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Up in Smoke: Uncovering a Lack of Evidence for Proton Pump Inhibitors as a Source of Tetrahydrocannibol Immunoassay False Positives.

Powers JL, Rasmussen NN, Hurst D, Strathmann FG.

Pain Med. 2017 Nov 8. doi: 10.1093/pm/pnx266. [Epub ahead of print]

PMID:
29126183
2.

The Type IX Secretion System Is Required for Virulence of the Fish Pathogen Flavobacterium columnare.

Li N, Zhu Y, LaFrentz BR, Evenhuis JP, Hunnicutt DW, Conrad RA, Barbier P, Gullstrand CW, Roets JE, Powers JL, Kulkarni SS, Erbes DH, García JC, Nie P, McBride MJ.

Appl Environ Microbiol. 2017 Nov 16;83(23). pii: e01769-17. doi: 10.1128/AEM.01769-17. Print 2017 Dec 1.

3.

Thyroglobulin Antibody Screen Prior to Mass Spectrometry Provides Measurable Cost Savings and Optimal Laboratory Utilization.

Powers JL, Strathmann FG, Straseski JA.

Am J Clin Pathol. 2017 Mar 1;147(3):309-314. doi: 10.1093/ajcp/aqw228.

PMID:
28395053
4.

Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1.

Powers JL, Buys SS, Fletcher D, Melis R, Johnson-Davis KL, Lyon E, Malmberg EM, McMillin GA.

J Clin Pharmacol. 2016 Dec;56(12):1570-1581. doi: 10.1002/jcph.771. Epub 2016 Jun 21.

PMID:
27198207
5.

The psychology and practice of youth-adult partnership: bridging generations for youth development and community change.

Zeldin S, Christens BD, Powers JL.

Am J Community Psychol. 2013 Jun;51(3-4):385-97. doi: 10.1007/s10464-012-9558-y.

PMID:
23054170
6.

A novel model of rheumatoid arthritis-associated interstitial lung disease in SKG mice.

Keith RC, Powers JL, Redente EF, Sergew A, Martin RJ, Gizinski A, Holers VM, Sakaguchi S, Riches DW.

Exp Lung Res. 2012 Mar;38(2):55-66. doi: 10.3109/01902148.2011.636139. Epub 2011 Dec 20.

PMID:
22185348
7.

Online Patient Safety Climate Survey: Tool Development and Lessons Learned.

Connelly LM, Powers JL.

In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in Patient Safety: From Research to Implementation (Volume 4: Programs, Tools, and Products). Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Feb.

8.

Lactate dehydrogenase kinetics and inhibition using a microplate reader.

Powers JL, Kiesman NE, Tran CM, Brown JH, Bevilacqua VL.

Biochem Mol Biol Educ. 2007 Jul;35(4):287-92. doi: 10.1002/bmb.74. Epub 2007 Jul 3.

9.

Engaging youth in participatory research and evaluation.

Powers JL, Tiffany JS.

J Public Health Manag Pract. 2006 Nov;Suppl:S79-87.

PMID:
17035908
10.

The virtual cutting edge: the internet and adolescent self-injury.

Whitlock JL, Powers JL, Eckenrode J.

Dev Psychol. 2006 May;42(3):407-17.

PMID:
16756433
11.

Etanercept as monotherapy in patients with psoriasis.

Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB; Etanercept Psoriasis Study Group.

N Engl J Med. 2003 Nov 20;349(21):2014-22.

12.
13.

Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit.

Traynelis SF, Burgess MF, Zheng F, Lyuboslavsky P, Powers JL.

J Neurosci. 1998 Aug 15;18(16):6163-75.

14.

Mechanism-based inactivation of dopamine beta-monooxygenase in adrenal chromaffin cells.

May SW, Young FK, Powers JL, Gill-Woznichak MM.

Biochem Biophys Res Commun. 1996 Nov 12;228(2):278-84.

PMID:
8920906
15.
16.
17.
18.

Accepting and refusing assignments.

Powers JL.

Nurs Manage. 1993 Sep;24(9):64-6, 68.

PMID:
8367122
19.

Maltreatment among runaway and homeless youth.

Powers JL, Eckenrode J, Jaklitsch B.

Child Abuse Negl. 1990;14(1):87-98.

PMID:
2310977
20.

The maltreatment of adolescents.

Powers JL, Eckenrode J.

Child Abuse Negl. 1988;12(2):189-99.

PMID:
3260810
21.

Spironolactone-associated digoxin radioimmunoassay interference.

Silber B, Sheiner LB, Powers JL, Winter ME, Sadée W.

Clin Chem. 1979 Jan;25(1):48-50.

22.

Determination of quinidine by high-performance liquid chromatography.

Powers JL, Sadee W.

Clin Chem. 1978 Feb;24(2):299-302.

23.

Measurement of procainamide and N-acetylprocainamide in serum by high-performance liquid chromatography.

Shukur LR, Powers JL, Marques RA, Winter ME, Sadée W.

Clin Chem. 1977;23(4):636-8.

PMID:
844158
24.

Gamma glutamyl transpeptidase in chronic obstructive pulmonary disease.

Barton AD, Powers JL, Lourenco RV.

Proc Soc Exp Biol Med. 1974 May;146(1):99-103. No abstract available.

PMID:
4151230
25.

Biochemical characteristics affecting the consistency of bronchial secretions.

Barton AD, Powers JL, Lopata M, Lourenco RV.

Chest. 1973 Apr;63:Suppl:59S-62S. No abstract available.

PMID:
4695752
26.

Airborne particle size analysis; a composite bibliography. IDO-12051.

Collins JT Jr, Harrie WJ, Stromberg DD, Powers JL.

IDO Rep. 1966 May:1-33. No abstract available.

PMID:
5328089
27.

Report of the National Formulary Antianemia Preparations Advisory Board.

ROBBINS AB, SCHWARTZ SO, POWERS JL, HAGEN PS, RUNDLES W, WASSERMAN LR.

JAMA. 1961 Mar 18;175:994-6. No abstract available.

PMID:
13742059
28.

The national formulary; its value to the chiropodist.

POWERS JL.

J Natl Assoc Chirop. 1956 Jun;46(6):382-5. No abstract available.

PMID:
13320111
29.

The National Formulary.

POWERS JL.

Public Health Rep. 1953 May;68(5):513-5. No abstract available.

30.

Use survey of certain N. F. VIII drugs.

POWERS JL, GREEN MW.

Bull Am Pharm Assoc. 1948 May-Jun;16(5-6):94-120. No abstract available.

PMID:
18865147
31.

A statistical study of weight tolerances of dry-filled ampuls.

GREEN MW, POWERS JL.

Bull Am Pharm Assoc. 1948 May-Jun;16(5-6):81-94. No abstract available.

PMID:
18865146
32.

Suggested assays for some official mercury-containing drugs.

GREEN N, GREEN MW, POWERS JL.

Bull Am Pharm Assoc. 1947 May-Jun;15(5-6):101-6. No abstract available.

PMID:
20252787
33.

An approach to a uniform assay for official drugs containing mercury.

GREEN N, GREEN MW, POWERS JL.

Bull Am Pharm Assoc. 1947 May-Jun;15(5-6):92-101. No abstract available.

PMID:
20252786
34.

A statistical approach to the determination of the weight tolerances of dry-filled ampuls.

GREEN MW, KELLY KL, POWERS JL.

Bull Am Pharm Assoc. 1947 Jan-Feb;15(1-2):1-8. No abstract available.

PMID:
20295488
35.

Drug trends and the new National Formulary.

POWERS JL.

J Am Pharm Assoc Am Pharm Assoc (Baltim). 1946 Oct;7(10):436-42. No abstract available.

PMID:
20274512
36.

The new National Formulary (VIII).

POWERS JL.

Merck Rep. 1946 Jul;55:27-30. No abstract available.

PMID:
20989236
37.

Tolerances of National Formulary tablets and capsules.

GREEN MW, POWERS JL.

Bull Am Pharm Assoc. 1946 May-Jun;14:81-96. No abstract available.

PMID:
20985302

Supplemental Content

Loading ...
Support Center